A5175 -A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor- And Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations For Initial Treatment Of HIV-1 Infected Individuals From Resource-Limited Settings (PEARLS) Trial